Stocks · News reference

BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target

Aug 4, 2026, 9:15 AMBenzinga Newsdesk

BTIG analyst Mark Massaro reiterates GeneDx Holdings (NASDAQ:WGS) with a Buy and maintains $90 price target.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 4, 2026, 9:15 AM
Checked: Aug 4, 2026, 9:15 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 9, 2026, 12:40 PMBenzinga Newsdesk
GeneDx Partners With Beren Therapeutics To Launch The NPC GenomeComplete Sponsored Testing Program For Niemann-Pick Disease Type C
The program provides no-cost comprehensive genome sequencing for eligible pediatric patients with clinical findings, family history, or biomarker evidence suggestive of Niemann-Pick Disease Type C (NPC), helping address
WGS
BenzingaAug 26, 2026, 2:57 PMErica Kollmann
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
Ondas, SoundHound AI and CleanSpark are in the top ten most-heavily shorted stocks in the market right now.
ANDG CAR CHH CHTR CLSK
BenzingaAug 24, 2026, 12:34 PMBenzinga Newsdesk
GeneDx Announces New Data Published In Genetics In Medicine Demonstrating First‑Tier Rapid Genome Sequencing Improves Diagnostic Rates, Patient Outcomes, And Operational Efficiency In Pediatric Care
WGS
BenzingaAug 4, 2026, 12:27 PMBenzinga Newsdesk
GeneDx Holdings shares are trading higher after the company reported better-than-expected Q2 financial results. Also, Canaccord Genuity raised its price target from $75 to $90.
WGS